“One of the biggest challenges in the management of RA is monitoring disease effectively, in order to avoid missing flare-ups,” said Dr Walker and colleagues, adding that the use of patient-reported outcomes to complement disease monitoring is recommended by the European League Against Rheumatism.
Upadacitinib Is Effective in Patients with Active RA with Inadequate Response to Conventional Synthetic DMARDs
This is an analysis of the double-blind, placebo-controlled period 1 of the randomized phase 3 study that evaluated upadacitinib in patients with inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).
The MONARCH trial showed that subcutaneous sarilumab was superior to adalimumab monotherapy in reducing disease activity and improving physical function in active rheumatoid arthritis. Patients who completed the initial double-blind phase in MONARCH continued to the open-label extension and received sarilumab monotherapy.
No Increased Cardiovascular Risk in Patients with RA Who Newly Initiated Tocilizumab versus Abatacept
Sarilumab, a human monoclonal antibody against interleukin-6 receptors, is currently approved for patients with moderate-to-severe rheumatoid arthritis (RA), based on efficacy and safety data from several clinical trials.
Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
The analysis of the COMPACT trial sought to demonstrate noninferiority of tocilizumab alone versus tocilizumab plus methotrexate (MTX) in maintaining clinical response in patients with rheumatoid arthritis (RA) who achieve low disease activity (LDA) following treatment with tocilizumab plus MTX.
Suboptimal EHR Reporting of Clinical Measures in Patients with RA Receiving a Biologic or Targeted Synthetic DMARD
This retrospective analysis of the Optum One electronic health record (EHR) databases from various Integrated Delivery Networks (IDNs) and large group practices across the United States was conducted to examine the EHR reporting rates of several clinical measures among patients with rheumatoid arthritis (RA) who received a biologic or a targeted synthetic disease-modifying antirheumatic drug (tsDMARD).
This study explored the effects of sarilumab, an anti–interleukin-6Rα human monoclonal antibody, or placebo in combination with disease-modifying antirheumatic drugs (DMARDs) on fasting glucose and glycosylated hemoglobin (HbA1c) in diabetic and nondiabetic patients with rheumatoid arthritis (RA).
This study assessed the comparative effectiveness of the Janus kinase 1/2 inhibitors, tofacitinib and baricitinib, in patients with rheumatoid arthritis (RA) using a network meta-analysis and Cochrane systematic review of randomized controlled trials from 7 electronic databases and 2 trial registries.
Page 1 of 9
Results 1 - 10 of 83
Results 1 - 10 of 83